Atatürk Üniversitesi Atatürk Üniversitesi
Ara
Yayınlara dön
Makale Tam Makale Uluslararası 2024

mucormycosis: The international ID-IRI study

Meyha ŞAHİN, Mesut YILMAZ, Ali MERT, Behrouz Naghili, Fatemeh Ravanbakhsh, Mojtaba Varshochi, Ilad Alavi Darazam, Mohammad Javad Ebrahimi, Maral Moafi, Hamed Azhdari Tehrani, Amjad Mahboob, Naveed Rashid, Ejaz Ahmed Khan, Atousa Hakamifard, Gülden Eser-Karlidag, Abdolreza Babamahmoodi, Amani El-Kholy, Sayed Hussain Mosawi, Ayşe Albayrak, Jamal Wadi Al Ramahi, Syam Kumar Addepalli, Şafak Özer Balin, Asfandiyar Khan, Nirav Pandya, Esra Gurbuz, Gülden Sincan, Hadia Azami, Rıdvan Dumlu, Reham Khedr, Rezaul Karim Ripon, Sevil Alkan, Şükran Kose, Bahadır Ceylan, Hakan Erdem

Medical Mycology Cilt 62 · Sayı 7 · 01.07.2024
DOI ile aç

Özet

The emergence of COVID-19, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), triggered a global pandemic. Concurrently, reports of mucormycosis cases surged, particularly during the second wave in India. This study aims to investigate mortality factors in COVID-19-associated mucormycosis (CAM) cases, exploring clinical, demographic, and therapeutic variables across mostly Asian and partly African countries. A retrospective, cross-sectional analysis of CAM patients from 22 medical centers across eight countries was conducted, focusing on the first 3 months post-COVID-19 diagnosis. Data collected through the ID-IRI included demographics, comorbidities, treatments, and outcomes. A total of 162 CAM patients were included. The mean age was 54.29 ± 13.04 years, with 54% male. Diabetes mellitus (85%) was prevalent, and 91% had rhino-orbital-cerebral mucormycosis. Surgical debridement was performed in 84% of the cases. Mortality was 39%, with advanced age (hazard ratio [HR] = 1.06, [P < .001]), rituximab use (HR = 21.2, P = .05), and diabetic ketoacidosis (HR = 3.58, P = .009) identified as risk factors. The mortality risk increases by approximately 5.6% for each additional year of age. Surgical debridement based on organ involvement correlated with higher survival (HR = 8.81, P < .001). The utilization of rituximab and diabetic ketoacidosis, along with advancing age, has been associated with an increased risk of mortality in CAM patients. A combination of antifungal treatment and surgical intervention has demonstrated a substantial improvement in survival outcomes.

Anahtar kelimeler

COVID-19 Mortality COVID-19-associated mucormycosis immunosuppression

Sürdürülebilir Kalkınma Amaçları

  • SKA 3: Sağlıklı Bireyler

Atıf için künye

ŞAHİN, M., YILMAZ, M., MERT, A., Naghili, B., Ravanbakhsh, F., Varshochi, M., Darazam, I. A., Ebrahimi, M. J., Moafi, M., Tehrani, H. A., Mahboob, A., Rashid, N., Khan, E. A., Hakamifard, A., Eser-Karlidag, G., Babamahmoodi, A., El-Kholy, A., Mosawi, S. H., Albayrak, A., … Erdem, H. (2024). mucormycosis: The international ID-IRI study. Medical Mycology, 62(7). https://doi.org/10.1093/mmy/myae064

BibTeX 
@article{sahin2024-225079,
  author = {ŞAHİN, Meyha and YILMAZ, Mesut and MERT, Ali and Naghili, Behrouz and Ravanbakhsh, Fatemeh and Varshochi, Mojtaba and Darazam, Ilad Alavi and Ebrahimi, Mohammad Javad and Moafi, Maral and Tehrani, Hamed Azhdari and Mahboob, Amjad and Rashid, Naveed and Khan, Ejaz Ahmed and Hakamifard, Atousa and Eser-Karlidag, Gülden and Babamahmoodi, Abdolreza and El-Kholy, Amani and Mosawi, Sayed Hussain and Albayrak, Ayşe and Al Ramahi, Jamal Wadi and Addepalli, Syam Kumar and Balin, Şafak Özer and Khan, Asfandiyar and Pandya, Nirav and Gurbuz, Esra and Sincan, Gülden and Azami, Hadia and Dumlu, Rıdvan and Khedr, Reham and Ripon, Rezaul Karim and Alkan, Sevil and Kose, Şükran and Ceylan, Bahadır and Erdem, Hakan},
  title = {mucormycosis: The international ID-IRI study},
  journal = {Medical Mycology},
  year = {2024},
  volume = {62},
  number = {7},
  issn = {1369-3786},
  doi = {10.1093/mmy/myae064},
  url = {https://akademik.atauni.edu.tr/yayinlar/225079-mucormycosis-the-international-id-iri-study}
}